An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

  • Cancer
  • Gastric and Gastroesophageal Junction Carcinoma
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Active, not recruiting

This study runs in
Country
  • China
Study Identifier:

NCT05251948 YO43408

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced gastric carcinoma (GC) or gastroesophageal junction carcinoma (GEJC). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and modify the participant population. Cohort 1 will enroll participants with inoperable locally advanced, metastatic, or advanced GC or GEJC, with adenocarcinoma confirmed as the predominant histology, who have not received prior systemic therapy for advanced or metastatic disease. Eligible participants will initially be randomly assigned to one of treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.

      Hoffmann-La Roche Sponsor
      Phase 1/Phase 2 Phase
      NCT05251948, YO43408 Study Identifier
      Atezolizumab, Capecitabine, Oxaliplatin, Tiragolumab Treatments
      Gastric and Gastroesophageal Junction Carcinoma Condition
      Official Title

      A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (MORPHEUS C-Gastric and Gastroesophageal Junction Carcinoma)

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria

      Inclusion Criteria for Stage 1:

      • ECOG Performance Status of 0 or 1
      • Inoperable locally advanced, metastatic, or advanced GC or GEJC, with adenocarcinoma confirmed as the predominant histology
      • No prior systemic treatment for advanced or metastatic disease
      • Life expectancy >= 3 months, as determined by the investigator
      • Human epidermal growth factor receptor 2 (HER2)-negative tumors
      • Measurable disease according to RECIST v1.1
      • Adequate hematologic and end-organ function
      • Patients without hepatitis B virus (HBV) infection at screening
      • Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening
      • Negative HIV test at screening
      • For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs, as outlined for each specific treatment arm
      • For men: agreement to remain abstinent or use contraception, and agreement to refrain from donating sperm, as outlined for each specific treatment arm
      Exclusion Criteria

      Exclusion Criteria for Stage 1:

      • Prior treatment with CD137 agonists or immune checkpoint blockade therapies
      • Treatment with investigational therapy within 28 days prior to initiation of study treatment
      • Any contraindications to any of the study drugs of the chemotherapy regimen
      • Eligible only for the control arm
      • Patients with a signet ring cells dominant carcinoma
      • Symptomatic, untreated, or actively progressing CNS metastases
      • History of leptomeningeal disease
      • Active or history of autoimmune disease or immune deficiency
      • Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
      • History of malignancy other than GC or GEJC within 2 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death

      Exclusion Criteria for Tiragolumab-Containing Arm:

      • Prior treatment with an anti-TIGIT agent
      • Active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other studies on ForPatients in related disease areas.

      Gastric and Gastroesophageal Junction Carcinoma

      Clinical Research Explained

      Information about what clinical studies and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now